RA Capital Management - Q2 2016 holdings

$722 Million is the total value of RA Capital Management's 32 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 33.3% .

 Value Shares↓ Weighting
WVE  WAVE LIFE SCIENCES LTD$146,664,000
+49.1%
7,088,6510.0%20.31%
+61.5%
ACHN  ACHILLION PHARMACEUTICALS INC$93,859,000
+1.0%
12,033,2200.0%13.00%
+9.4%
AXGT  AXOVANT SCIENCES LTD$64,200,000
+11.8%
5,000,0000.0%8.89%
+21.2%
AVXS SellAVEXIS INC$50,923,000
+37.3%
1,339,382
-1.6%
7.05%
+48.7%
ACRS  ACLARIS THERAPEUTICS INC$48,534,000
-2.5%
2,627,7190.0%6.72%
+5.6%
NKTR BuyNEKTAR THERAPEUTICS$45,890,000
+5.0%
3,224,854
+1.4%
6.35%
+13.7%
ASND BuyASCENDIS PHARMA A Ssponsored adr$45,289,000
+13.0%
3,412,857
+57.9%
6.27%
+22.4%
TGTX  TG THERAPEUTICS INC$27,462,000
-28.9%
4,531,7140.0%3.80%
-23.0%
ARDX BuyARDELYX INC$20,186,000
+12.9%
2,312,243
+0.5%
2.80%
+22.3%
ZGNX  ZOGENIX INC$19,732,000
-12.9%
2,451,2370.0%2.73%
-5.6%
VTAE  VITAE PHARMACEUTICALS INC$16,994,000
+62.7%
1,575,0000.0%2.35%
+76.3%
AIMT  AIMMUNE THERAPEUTICS INC$13,990,000
-20.2%
1,292,9400.0%1.94%
-13.6%
ADHD  ALCOBRA LTD$13,618,000
+18.5%
3,032,9110.0%1.89%
+28.4%
PRTO  PROTEON THERAPEUTICS INC$13,064,000
+3.7%
1,626,9310.0%1.81%
+12.4%
AQXP  AQUINOX PHARMACEUTICALS INC$11,201,000
-24.9%
1,691,9770.0%1.55%
-18.7%
SBBP SellSTRONGBRIDGE BIOPHARMA PLC$10,648,000
-13.2%
2,675,338
-0.6%
1.47%
-6.0%
NTRA  NATERA INC$9,453,000
+26.7%
783,5200.0%1.31%
+37.4%
DMTX  DIMENSION THERAPEUTICS INC$9,288,000
-23.4%
1,548,0330.0%1.29%
-17.0%
BCRX  BIOCRYST PHARMACEUTICALS$8,491,000
+0.4%
2,989,7950.0%1.18%
+8.8%
DRNA  DICERNA PHARMACEUTICALS INC$7,286,000
-44.0%
2,428,5710.0%1.01%
-39.4%
SGMO SellSANGAMO BIOSCIENCES INC$6,751,000
-49.6%
1,165,938
-47.3%
0.94%
-45.4%
AGRX SellAGILE THERAPEUTICS INC$6,492,000
-1.8%
853,151
-19.8%
0.90%
+6.4%
TENX  TENAX THERAPEUTICS INC$6,118,000
+24.9%
2,389,7000.0%0.85%
+35.3%
EIGR  EIGER BIOPHARMACEUTICALS INC$5,781,000
+18.2%
291,7000.0%0.80%
+28.0%
BGNE  BEIGENE LTDsponsored adr$5,066,000
+1.7%
170,0000.0%0.70%
+10.0%
CDTX SellCIDARA THERAPEUTICS INC$4,235,000
-71.6%
410,809
-65.0%
0.59%
-69.3%
AKTX SellAKARI THERAPEUTICS PLCsponsored adr$3,160,000
+21.6%
234,240
-9.1%
0.44%
+31.9%
AGLE NewAEGLEA BIOTHERAPEUTICS INC$2,535,000521,550
+100.0%
0.35%
MRUS NewMERUS N V$1,898,000237,599
+100.0%
0.26%
ZYNE SellZYNERBA PHARMACEUTICALS INC$1,736,000
-63.8%
253,468
-50.0%
0.24%
-60.8%
ABIO SellARCA BIOPHARMA INC$1,632,000
-39.6%
562,693
-27.7%
0.23%
-34.5%
DNAI SellPRONAI THERAPEUTICS INC$59,000
-98.6%
29,719
-95.1%
0.01%
-98.5%
APHB ExitAMPLIPHI BIOSCIENCES CORP$0-53,600
-100.0%
-0.03%
DSCI ExitDERMA SCIENCES INC$0-81,239
-100.0%
-0.03%
BPMC ExitBLUEPRINT MEDICINES CORP$0-56,442
-100.0%
-0.13%
ExitNEURODERM LTD$0-144,671
-100.0%
-0.26%
NVLS ExitNIVALIS THERAPEUTICS INC$0-612,863
-100.0%
-0.33%
AGTC ExitAPPLIED GENETIC TECHNOL CORP$0-236,059
-100.0%
-0.42%
RGLS ExitREGULUS THERAPEUTICS INC$0-1,045,119
-100.0%
-0.93%
COLL ExitCOLLEGIUM PHARMACEUTICAL INC$0-486,557
-100.0%
-1.13%
ACOR ExitACORDA THERAPEUTICS INC$0-498,159
-100.0%
-1.68%
CPXX ExitCELATOR PHARMACEUTICALS INC$0-1,414,114
-100.0%
-1.99%
ARNA ExitARENA PHARMACEUTICAL S INC$0-9,364,105
-100.0%
-2.36%
CHRS ExitCOHERUS BIOSCIENCES INC$0-1,272,048
-100.0%
-3.45%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2016-08-15
Signatures

The EDGAR filing(s) were signed by:

About RA Capital Management

RA Capital Management is a Boston-based investment management firm that specializes in the healthcare sector. The firm was founded in 2001 by Peter Kolchinsky, a former biotech analyst at Lehman Brothers. Since then, RA Capital has grown to become one of the most respected healthcare investment firms in the world, with over $5 billion in assets under management.

The firm's investment strategy is focused on identifying and investing in companies that are developing innovative therapies and technologies that have the potential to transform the healthcare industry. RA Capital's team of experienced analysts and portfolio managers conduct extensive research and due diligence to identify the most promising investment opportunities in the healthcare sector.

RA Capital's portfolio includes a diverse range of companies, from early-stage startups to established biotech and pharmaceutical companies. Some of the notable companies in RA Capital's portfolio include Moderna, a biotech company that is developing a COVID-19 vaccine, and Intellia Therapeutics, a gene editing company that is developing therapies for genetic diseases.

Peter Kolchinsky, the founder and CEO of RA Capital, is a well-respected figure in the healthcare investment community. He is a frequent speaker at industry conferences and has authored several books on biotech investing. Other key members of RA Capital's management team include Rajeev Shah, the firm's COO, and Derek DiRocco, the Chief Investment Officer.

Overall, RA Capital Management is a highly respected investment firm that has a proven track record of identifying and investing in innovative healthcare companies. Investors who are interested in the healthcare sector may want to consider RA Capital as a potential investment opportunity.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ASCENDIS PHARMA A/S - ADR35Q3 202325.5%
WAVE LIFE SCIENCES PTE LTD32Q3 202326.3%
TG THERAPEUTICS INC30Q4 20216.3%
ZOGENIX INC26Q4 20219.5%
BIOCRYST PHARMACEUTICALS23Q1 20199.2%
DICERNA PHARMACEUTICALS INC23Q3 20195.8%
RHYTHM PHARMACEUTICALS INC22Q3 20234.4%
ACHILLION PHARMACEUTICALS INC19Q4 201717.2%
KALA PHARMACEUTICALS INC19Q1 20224.4%
SOLID BIOSCIENCES INC19Q3 20226.8%

View RA Capital Management's complete holdings history.

Latest significant ownerships (13-D/G)
RA Capital Management Q2 2016 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
CymaBay Therapeutics, Inc.September 22, 20236,940,0006.2%
BELLUS Health Inc.Sold outAugust 14, 202300.0%
Kinnate Biopharma Inc.Sold outAugust 14, 202300.0%
Vor Biopharma Inc.August 11, 202322,780,34333.7%
DICE Therapeutics, Inc.Sold outAugust 09, 202300.0%
Acumen Pharmaceuticals, Inc.July 25, 202314,981,61825.9%
Talaris Therapeutics, Inc.July 06, 20232,333,1755.5%
Aerovate Therapeutics, Inc.June 27, 20238,293,14830.0%
Satsuma Pharmaceuticals, Inc.Sold outJune 12, 202300.0%
ARYA Sciences Acquisition Corp VSold outMay 15, 202300.0%

View RA Capital Management's complete significant-ownership history.

Latest filings
TypeFiled
SC 13G2024-04-25
42024-04-15
42024-04-15
SC 13G2024-04-15
SC 13D/A2024-04-12
SC 13G2024-04-12
SC 13D/A2024-04-11
SC 13G2024-04-11
42024-04-04
SC 13G2024-04-04

View RA Capital Management's complete filings history.

Compare quarters

Export RA Capital Management's holdings